I don't know honestly, but it's a good question. They did have some early-stage collaborations to tide them through the 90's and 2000's. Along the way they had a couple of failed Phase III trials, therefore the occasional share price free-falls that must've been terrifying to watch. First drug approved for a limited economic market in 2008. Things only got interesting starting in 2009. Do you think Leo is holding out for too much?
Market Data 
Markets 
AI
